ArticleASN neuro2026
Intranasal Delivery of Proenkephalin-Expressing Differentiated Mesenchymal Stem Cells Attenuates Morphine Dependence Behaviors and Modulates Neurotrophic Factors in Rats.
Article in ASN neuro, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substance use disorder is a chronic relapsing condition characterized by persistent drug seeking, cognitive impairment, and neurobiological alterations in brain reward and memory circuits. Emerging evidence suggests that dysfunction of the endogenous opioid system and reduced neurotrophic signaling contribute to the pathophysiology of opioid dependence. Cell based therapeutic strategies may provide a novel approach to modulate these neural pathways. In the present experimental study, morphine dependence was induced in adult male rats using an escalating dose regimen. Animals were randomly allocated into control, morphine-dependent vehicle, and cell-treated groups. Proenkephalin-expressing differentiated mesenchymal stem cells (PENK-MSCs) were delivered via the intranasal route. Behavioral assessments were performed using conditioned place preference, novel object recognition, and the elevated plus maze to evaluate addiction related behaviors, cognitive performance, and anxiety like responses. Hippocampal brain derived neurotrophic factor (BDNF) expression was examined using immunohistochemistry. Morphine dependent rats exhibited significant behavioral alterations, including enhanced drug related preference, impaired recognition memory, and increased anxiety like behavior compared with control animals. In addition, hippocampal BDNF expression was significantly reduced following morphine exposure. Intranasal cell delivery significantly attenuated morphine-induced preference, reversed recognition memory deficits, mitigated anxiety-like behaviors, and upregulated hippocampal BDNF expression compared with the vehicle-treated morphine group. These findings demonstrate that intranasal delivery of PENK-MSCs attenuates behavioral deficits and promotes neurotrophic recovery in morphine-dependent rats. This approach may represent a promising experimental strategy for targeting neural mechanisms involved in substance use disorder, although further studies are required to confirm its long-term efficacy and translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.